Drugs / Prodencel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05533203 | Aug 2022 → Aug 2023 | castration-resistant prostate carcinoma | Shanghai Humantech Biotechnology Co. Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prodencel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05533203 ↗ |
| Modality | Vaccine | “dendritic cell vaccine” NCT05533203 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT05533203 ↗ |